Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Maintain and monitor long-term hematological and cytogenetic responses previously obtained by patients participating in the \[CAMN107A2109\] study
Chronic Myeloid Leukemia
DRUG: Nilotinib
Disease response (complete hematologic response, cytogenetic response) and progression at or until 24 months, depending of the case every 3 months, 3 - 24 months
Maintain and monitor long-term hematological and cytogenetic responses previously obtained by patients participating in the \[CAMN107A2109\] study